Terms: = Kidney tumors AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Prognosis
64 results:
1. Copper Death Inducer, FDX1, as a Prognostic Biomarker Reshaping Tumor Immunity in Clear Cell Renal Cell Carcinoma.
Jiang A; Ye J; Zhou Y; Zhu B; Lu J; Ge S; Qu L; Xiao J; Wang L; Cai C
Cells; 2023 Jan; 12(3):. PubMed ID: 36766692
[TBL] [Abstract] [Full Text] [Related]
2. Pyroptosis relates to tumor microenvironment remodeling and prognosis: A pan-cancer perspective.
Khan M; Ai M; Du K; Song J; Wang B; Lin J; Ren A; Chen C; Huang Z; Qiu W; Zhang J; Tian Y; Yuan Y
Front Immunol; 2022; 13():1062225. PubMed ID: 36605187
[TBL] [Abstract] [Full Text] [Related]
3. Tumor microenvironment immune subtypes for classification of novel clear cell renal cell carcinoma profiles with prognostic and therapeutic implications.
Wang Q; Hu J; Kang W; Wang J; Xiang Y; Fu M; Gao H; Huang Z
Medicine (Baltimore); 2021 Mar; 100(11):e24949. PubMed ID: 33725966
[TBL] [Abstract] [Full Text] [Related]
4. T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN-γ, TNF-α or il-2 production.
van Asten SD; de Groot R; van Loenen MM; Castenmiller SM; de Jong J; Monkhorst K; Haanen JBAG; Amsen D; Bex A; Spaapen RM; Wolkers MC
Oncoimmunology; 2021 Jan; 10(1):1860482. PubMed ID: 33537169
[TBL] [Abstract] [Full Text] [Related]
5. Immunotherapy in metastatic sarcomatoid renal cell carcinoma: A single institution experience.
Park JJ; Kellezi O; Hamasha R; Ali A; Alva AS
Cancer Treat Res Commun; 2020; 25():100251. PubMed ID: 33310369
[TBL] [Abstract] [Full Text] [Related]
6. SARS-CoV-2 Infection and High-Risk Non-Muscle-Invasive Bladder Cancer: Are There Any Common Features?
Busetto GM; Porreca A; Del Giudice F; Maggi M; D'Agostino D; Romagnoli D; Musi G; Lucarelli G; Palmer K; Colonna di Paliano A; Muto M; Hurle R; Terracciano D; de Cobelli O; Sciarra A; De Berardinis E; Ferro M
Urol Int; 2020; 104(7-8):510-522. PubMed ID: 32516772
[TBL] [Abstract] [Full Text] [Related]
7. PD-L1 detection using
Vento J; Mulgaonkar A; Woolford L; Nham K; Christie A; Bagrodia A; de Leon AD; Hannan R; Bowman I; McKay RM; Kapur P; Hao G; Sun X; Brugarolas J
J Immunother Cancer; 2019 Jun; 7(1):144. PubMed ID: 31155004
[TBL] [Abstract] [Full Text] [Related]
8. High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features.
Achkar T; Arjunan A; Wang H; Saul M; Davar D; Appleman LJ; Friedland D; Parikh RA
PLoS One; 2017; 12(12):e0190084. PubMed ID: 29261796
[TBL] [Abstract] [Full Text] [Related]
9. Dorsal Muscle Attenuation May Predict Failure to Respond to Interleukin-2 Therapy in Metastatic Renal Cell Carcinoma.
Otemuyiwa B; Derstine BA; Zhang P; Wong SL; Sabel MS; Redman BG; Wang SC; Alva AS; Davenport MS
Acad Radiol; 2017 Sep; 24(9):1094-1100. PubMed ID: 28341412
[TBL] [Abstract] [Full Text] [Related]
10. Treatment Outcome of Low-dose Interleukin-2 Therapy in Patients with Metastatic Renal Cell Carcinoma.
Takezawa Y; Izumi K; Shimura Y; Aerken M; Natsagdorji A; Iijima M; Shigehara K; Nohara T; Narimoto K; Kadono Y; Kitagawa Y; Konaka H; Mizokami A
Anticancer Res; 2016 Sep; 36(9):4961-4. PubMed ID: 27630356
[TBL] [Abstract] [Full Text] [Related]
11. [Metastatic renal cell carcinoma, back to the future].
Martins F; Berthold D
Rev Med Suisse; 2016 May; 12(519):994-8. PubMed ID: 27424427
[TBL] [Abstract] [Full Text] [Related]
12. Safety of available treatment options for renal cell carcinoma.
Derosa L; Albiges L; Massard C; Loriot Y; Fizazi K; Escudier B
Expert Opin Drug Saf; 2016 Aug; 15(8):1097-106. PubMed ID: 27142582
[TBL] [Abstract] [Full Text] [Related]
13. Durable Response to Treatment With Combination Radiotherapy and High-dose Interleukin-2 in Metastatic Chromophobe Variant Renal Cell Carcinoma.
Merriman J; Tward J; Albertson D; Dechet C; Agarwal N
J Immunother; 2016; 39(2):101-3. PubMed ID: 26849079
[TBL] [Abstract] [Full Text] [Related]
14. Clinical significance of serum soluble T cell regulatory molecules in clear cell renal cell carcinoma.
Masuda A; Arai K; Nishihara D; Mizuno T; Yuki H; Kambara T; Betsunoh H; Abe H; Yashi M; Fukabori Y; Yoshida K; Kamai T
Biomed Res Int; 2014; 2014():396064. PubMed ID: 25089268
[TBL] [Abstract] [Full Text] [Related]
15. Combined immunotherapy with low-dose il-2 plus IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected patients with lung metastasis and serum sodium level.
Akaza H; Tsukamoto T; Fujioka T; Tomita Y; Kitamura T; Ozono S; Miki T; Naito S; Zembutsu H; Nakamura Y
Jpn J Clin Oncol; 2011 Aug; 41(8):1023-30. PubMed ID: 21642665
[TBL] [Abstract] [Full Text] [Related]
16. Diagnosis and treatment of renal cell carcinoma in children: a report from the Polish pediatric rare tumor study group.
Stachowicz-Stencel T; Bien E; Balcerska A; Godzinski J; Synakiewicz A; Perek-Polnik M; Kurylak A; Pietras W; Kuzmicz M; Mizia-Malarz A; Rybczynska A; Nurzynska-Flak J
Klin Padiatr; 2011 May; 223(3):138-41. PubMed ID: 21509711
[TBL] [Abstract] [Full Text] [Related]
17. Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment.
Tostain J; Li G; Gentil-Perret A; Gigante M
Eur J Cancer; 2010 Dec; 46(18):3141-8. PubMed ID: 20709527
[TBL] [Abstract] [Full Text] [Related]
18. A pilot study of denileukin diftitox (DD) in combination with high-dose interleukin-2 (il-2) for patients with metastatic renal cell carcinoma (RCC).
Atchison E; Eklund J; Martone B; Wang L; Gidron A; Macvicar G; Rademaker A; Goolsby C; Marszalek L; Kozlowski J; Smith N; Kuzel TM
J Immunother; 2010 Sep; 33(7):716-22. PubMed ID: 20664355
[TBL] [Abstract] [Full Text] [Related]
19. [Renal cell carcinoma management and therapies in 2010].
Albouy B; Gross Goupil M; Escudier B; Massard C
Bull Cancer; 2010; 97():17-28. PubMed ID: 20418201
[TBL] [Abstract] [Full Text] [Related]
20. New therapeutic approaches in the management of metastatic renal cell carcinoma.
Gkialas IK; Papadopoulos G
J BUON; 2009; 14(3):399-404. PubMed ID: 19810129
[TBL] [Abstract] [Full Text] [Related]
[Next]
